|
Feb 17
|
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
|
|
Jan 17
|
CDE grants BTD to Innovent’s IBI343 for pancreatic cancer
|
|
Jan 17
|
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
|
|
Jan 16
|
Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Jan 16
|
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
|
|
Jan 6
|
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Jan 3
|
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
|
|
Jan 2
|
Innovent and Roche link on lung cancer therapy development
|
|
Jan 1
|
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
|